Alkem Laboratories Q2 net profit up 76.83% at Rs 614.89 crore
Alkem Laboratories Q2 result: Consolidated revenue from operations stood at Rs 3,440.17 crore, as compared to Rs 3,079.37 crore in the year-ago period, it added. Total expenses in the quarter were marginally higher at Rs 2,797.66 crore, as against Rs 2,727.71 crore in the same period a year ago, the company said.
Alkem Laboratories Q2 result: Alkem Laboratories Ltd on Tuesday reported a 76.83 per cent rise in consolidated net profit at Rs 614.89 crore for the second quarter ended September 30, on the back of lower raw material cost and lower intensity of price erosion in the US market. The company had posted a consolidated net profit of Rs 347.72 crore in the second quarter of the last fiscal year, Alkem Laboratories said in a regulatory filing.
Consolidated revenue from operations stood at Rs 3,440.17 crore, as compared to Rs 3,079.37 crore in the year-ago period, it added. Total expenses in the quarter were marginally higher at Rs 2,797.66 crore, as against Rs 2,727.71 crore in the same period a year ago, the company said.
"Continuing our trend of improved performance, Q2 builds on the momentum gained in Q1 with significant gross margin enhancements backed by lower raw material cost and lower intensity of price erosion in the US market and increased operating leverage, resulting in improved EBITDA margins," Alkem Laboratories Managing Director Sandeep Singh said. Domestic growth for the quarter remained subdued due to sporadic monsoon, he said, adding "we observed significant traction in the domestic market during September and anticipate continued momentum in the coming quarter" The company's India sales increased by 5 per cent to Rs 2,327.8 crore, as compared to Rs 2,216.1 crore in Q2FY23.
On the international business, Singh said both the US and non-US markets maintained robust performance, which was "evident in Q1 and continues to flourish". Alkem said its international sales grew by 27.1 per cent to Rs 1,054.2 crore, as compared to Rs 829.1 crore in the year-ago quarter.
"Our biosimilars portfolio is performing impressively, with Enzene's latest product addition (Ranibizumab), taking the product suite to 7, and witnessing significant traction in the domestic biosimilars market. "We are committed to carrying forward the momentum of better operational performance, building on our recent successes," Singh said.
For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
PM Modi has invested in this post office scheme; know his total worth as per Lok Sabha elections 2024 affidavit
SRH vs GT IPL 2024 Ticket Booking Online: Where and how to buy SRH vs GT tickets online - Check IPL Match 66 ticket price, other details
Top 7 SWP Mutual Funds: Rs 50 lakh investment, Rs 70K monthly pension for 10 years, and Rs 42.30 lakh balance value; know more details
Gold and Silver rate today (May 13, 2024): Precious metal under pressure; yellow metal near Rs 72,400, white metal above Rs 84,600
SIP Returns: How Rs 3,000, 5,000, and Rs 10,000 SIPs can help you build retirement corpus of Rs 1.06 cr, Rs 1.77 cr, and Rs 3.53 cr
TBO Tek IPO Listing LIVE Update: Bumper Debut! Share list at 55% premium - Buy, sell or hold? Check Anil Singhvi's view
04:33 PM IST